The expression pattern of SLC11A1 in the experimental model was consistent with the trends observed in our prior bioinformatics analysis and external validation datasets, thereby providing robust validation and further supporting the promising potential of SLC11A1 as a biomarker for NAFLD. The gene discussed is SLC11A1; the disease is metabolic dysfunction-associated steatotic liver disease.